Siteman Investment Program Research Development Awards (SIP RDAs)

2023 Cycle 2 Statements of Intent Window is Now Closed.
Next cycle’s RFA will be released in January 2024.

The SIP RDA will fund research projects twice per year. Currently, there are seven mechanisms available:

  • CLINICAL TRIAL CATEGORY
    • New Clinical Trial Mechanism; up to $300,000 over 3 years
    • Existing Clinical Trial Mechanism; up to $200,000 over 2 years
    • Phase 0/1 Brain Tumor Center (BTC) Clinical Trial Mechanism; up to $75,000 over 3 years
  • PRE-R01 CATEGORY
    • The Pre-R01 Mechanism; up to $200,000 over 2 years (includes projects with prevention and control focus)
    • Pre-R01 Mechanism for University of Missouri-Columbia Collaboration; up to $200,000 over 2 years
  • TEAM SCIENCE CATEGORY
    • Team Science Mechanism; up to $800,000 over 2 years
  • COE SUPPLEMENT CATEGORY
    • COE Supplement Mechanism; up to $50,000 over 1 year (may request up to $100,000 directs with pre-approval as outlined in the RFA)

Complete information on each mechanism can be found in the Request for Applications (RFA) each cycle. A RFA will be announced twice per year on the following schedule:

GENERAL SIP DATE GUIDELINES* Cycle 1 Cycle 2
Announcement: January 19 August 1
Statement of Intent deadline: March 2024 August 28
Full applications due: April 2024 September 25
Anticipated decision notices: June 2024 December 15
Start dates: July 1 January 1
*Dates may vary based on weekends, holidays, and other unforeseen circumstances.

Please consult the specific cycle’s RFA announcement for official deadlines.

2023 Cycle 2 Official Dates

Announcement: August 1, 2023
Statement of Intent Submission deadline: August 28, 2023 at 4pm CST
Application deadline: September 25, 2023 at 4pm CST
Anticipated decision notice: December 15, 2023
Start date: January 1, 2024

2023 Cycle 2 Application Documents

SIP RDA Request for Applications (RFA) – NEW: Guidelines color-coded by category
SIP RDA Application Cover Sheet Form – (required – updated 09/2023)
SIP RDA Clinical Trial Category Budget Form – (required – updated 07/2020)

Success Rates

Success rates have been computed over the span of SIP RDA by mechanism and include applications that were scientifically reviewed. Success rates are determined by dividing the number of applications funded by the total number of applications reviewed. The current success rate for the Pre-R01 Category is 20%.

Re-submissions are welcome and encouraged every cycle. The success rate for re-submissions across all mechanisms is 31%.

Previous Awardees

For a list of Previous SIP RDA Awardees, click HERE.

Contact

Contact Steve Baer at Siteman Cancer Center for more information or any questions, [email protected].